Review On : Advancement in anticancer Drug development

Recent years have witnessed an impressive progress in the treatment of malignancies with the use of anticancer drugs which are much more selective than the commonly used chemotherapy agents. Highlights include targeted therapy like tyrosine kinase inhibitors which targets specific molecular link to tumor growth and immunotherapy like immune checkpoint inhibitors and CAR T-cell therapies that use the body’s own immune system against cancer. Precision medicine based on biomarkers offers a possibility to deliver a certain therapy depending on the genetic predisposition of a patient, and new approaches in drug delivery, such as nanotechnology, improve the efficiency of treatments and diminish the adverse effects. New knowledge of the cancer drug resistance factors prompted the development of its successors and combinations, providing approaches to fight this disease’s shift. Also, the present revolutionary technologies like gene editing-CRISPR and the AI-driven drug discovery converge into the future thematic area of cancer treatment. However, alongside these advancements there are issues like resistance, side effects and affordability and therefore there still is significant research needing to be done in order to enhance the patients’ quality of life.